STOCK TITAN

BioLineRX (BLRX) Stock News

BLRX NASDAQ

BioLineRx Ltd. develops oncology and rare-disease therapies, with recurring updates centered on GLIX1, APHEXDA (motixafortide), and motixafortide development in solid tumors.

Company news covers GLIX1 clinical development for glioblastoma and other solid tumors under its Hemispherian collaboration, intellectual-property developments tied to GLIX1, financial results, and corporate updates. APHEXDA is approved in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma and is commercialized by partners, while BioLineRx has retained motixafortide rights for solid-tumor programs including metastatic pancreatic cancer.

Rhea-AI Summary

BioLineRx (BLRX) will release its unaudited third-quarter 2026 financial results on November 23, 2026, before U.S. markets open. The quarter ended September 30, 2026. Chief Executive Officer Philip Serlin will speak on the 8:30 a.m. EST conference call that day.

The company’s event page will carry a live webcast, with a replay available approximately two hours after the call ends. A separate dial-in replay will be available through November 25, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
earnings date
-
Rhea-AI Summary

BioLineRx (BLRX) signed an agreement with Soleus Capital Management and its affiliates to sell future APHEXDA royalties for a one-time $5.6 million payment. Soleus will acquire BioLineRx’s 14.4% royalty interest in future APHEXDA net sales under its license with Ayrmid Pharma. BioLineRx retains rights to potential commercial milestone payments and royalties attributable to periods before closing. The deal is expected to close on or about November 30, 2026.

BioLineRx plans to use the non-dilutive proceeds to support research and development, including GLIX1, and to make a partial loan repayment to BlackRock EMEA Venture and Growth Lending. In connection with that repayment, BioLineRx’s current $4 million minimum cash balance requirement will be eliminated. The GLIX1 Phase 1/2a trial is enrolling the fourth of five planned dosing cohorts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
none
-
Rhea-AI Summary

BioLineRx (BLRX) and Hemispherian presented GLIX1 clinical-study and preclinical updates for glioblastoma, a brain cancer, at the SNO annual meeting. Dosing has begun in the fourth cohort of the ongoing Phase 1/2a study, with no significant treatment-emergent adverse events observed. BioLineRx expects study results in the first half of 2027. Remaining cohorts will include patients treated before surgery to assess drug penetration and biological activity directly in human brain tumors.

In preclinical models, GLIX1 eradicated tumors and prolonged survival in SNB19, inhibited tumor growth dose-dependently in U87MG, and inhibited growth in a temozolomide-resistant patient-derived model where temozolomide was ineffective. In U87MG, GLIX1 reached the brain at all tested doses and increased tumor 5hmC, a marker of TET2 enzyme activity, dose-dependently; these increases correlated with tumor growth inhibition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.54%
Tags
Rhea-AI Summary

BioLineRx (BLRX) and Hemispherian presented preclinical results showing GLIX1 synergy with PARP inhibitors in ovarian cancer models at ESMO 2026. In cell lines with functioning homologous recombination (HR), a DNA-repair process, GLIX1 combinations with olaparib, veliparib and niraparib produced ZIP synergy scores of 10.9–43.2, measuring combined activity beyond expected individual effects.

In a 28-day study using a patient-derived ovarian tumor model in mice, GLIX1 at 50 mg/kg daily plus olaparib at 10 mg/kg daily significantly inhibited tumor growth versus vehicle control. The combination outperformed either drug alone at its respective optimal dose and showed inhibition comparable to cisplatin. BioLineRx plans an ovarian cancer expansion arm in its ongoing Phase 1/2a GLIX1 trial in glioblastoma, which has enrolled three dose-level patient cohorts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
Rhea-AI Summary

BioLineRx (BLRX) and Hemispherian will present two GLIX1 posters at the Society for Neuro-Oncology annual meeting on November 13, 2026. Both presentations are scheduled for 7:30–9:30 p.m. EST at the Pennsylvania Convention Center in Philadelphia.

One poster covers preclinical research evaluating GLIX1 across multiple glioblastoma models, including a model resistant to temozolomide chemotherapy. The other describes the design of the ongoing Phase 1/2a trial evaluating GLIX1 in patients with recurrent or progressive high-grade glioma and other solid tumors. The clinical trial began in the first quarter of 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
none
-
Rhea-AI Summary

BioLineRx (BLRX)/b) and Hemispherian will present new GLIX1 preclinical data and its Phase 1/2a trial design at EANO 2026 in Rome.One abstract, selected for a mini-oral session on September 25, 2026, details GLIX1’s potent anti-tumor activity in orthotopic glioblastoma xenograft models, where oral dosing produced dose-dependent tumor growth inhibition and survival benefit at all tested doses, with brain exposure reaching 68–85% of plasma levels. A second e-poster describes the actively enrolling, open-label, multicenter Phase 1/2a trial (NCT07464925) of GLIX1, an oral TET2 activator, in up to 30 patients with recurrent or progressive WHO grade 3/4 glioma, using a BOIN design across up to 5 dose levels, with primary endpoints of safety, tolerability, and MTD/RP2D.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
Rhea-AI Summary

BioLineRx (NASDAQ/TASE: BLRX) reported unaudited Q2 2026 results and pipeline progress. Royalty revenues were $0.3 million, broadly flat year over year, mainly from APHEXDA sales of $1.6 million, generating $0.3 million in royalty income. Research and development expenses rose to $2.9 million and general and administrative expenses to $0.9 million, driving a net loss of $4.3 million versus $3.9 million in Q2 2025.

Cash, cash equivalents and short-term deposits totaled $13.1 million as of June 30, 2026, with cash runway guided into the first half of 2027. According to BioLineRx, a $3.75 million equity offering signed on August 27, 2026 is expected to close around August 31, 2026.

Clinically, the second of five planned cohorts is dosing in the Phase 1/2a GLIX1 glioblastoma study, with a third cohort expected to start in September, supported by new preclinical GBM and ovarian cancer data and multiple upcoming conference presentations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
-
Rhea-AI Summary

BioLineRx (NASDAQ: BLRX) announced a definitive agreement to sell an aggregate of 1,348,921 ADSs (or ADS equivalents) at $2.78 per ADS in a registered direct offering, plus accompanying warrants via a concurrent private placement to purchase up to 2,023,382 ADSs at an exercise price of $2.78.

The warrants will expire five years from issuance. Gross proceeds are expected to be $3.75 million before fees and expenses, with closing anticipated on or about August 31, 2026, subject to customary conditions. BioLineRx intends to use net proceeds for research and development, working capital and general corporate purposes.

In connection with the offering, BioLineRx agreed to amend outstanding warrants held by the investor to purchase 277,273 ADSs, reducing the exercise price to $2.78 and extending the expiration to August 31, 2031.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.80%
Tags
private placement offering
-
Rhea-AI Summary

BioLineRx (NASDAQ: BLRX) announced it will release unaudited financial results for the second quarter ended June 30, 2026, on Monday, August 31, 2026, before U.S. markets open. Management will host a conference call at 8:30 a.m. EDT, featuring remarks by CEO Philip Serlin.

Investors can join the call by dialing +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and replay will be available via the event page on the company’s website. A dial-in replay will be accessible until September 1, 2026, at +1-888-295-2634 (U.S.) or +972-3-925-5904 (international).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.00%
Tags
earnings date
Rhea-AI Summary

BioLineRx (NASDAQ/TASE: BLRX) and Hemispherian announced acceptance of an e-Poster at ESMO 2026 presenting pre-clinical data showing strong synergy between GLIX1, a TET2-activating small molecule, and PARP inhibitors in HR-proficient ovarian cancer cell lines. The presentation will be held October 23–27, 2026, in Madrid.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
none

FAQ

What is the current stock price of BioLineRX (BLRX)?

BioLineRX (BLRX) last closed at $0.9639.

What is the market cap of BioLineRX (BLRX)?

The market cap of BioLineRX (BLRX) is approximately $4.8M.